Table 2.
Effects of cryostorage-related anxiety on perceived stress and somatic symptom severity.
| Cryostorage-related anxiety levels | The UK survey |
The US survey |
||
|---|---|---|---|---|
| PSS change (95% CI) | PHQ-15 change (95% CI) | PSS change (95% CI) | PHQ-15 change (95% CI) | |
| None | Ref | Ref | Ref | Ref |
| Mild | 3.89 (0.85–6.94) | 3.25 (0.57–5.92) | 2.49 (0.02–4.97) | 1.96 (−0.34 to 4.25) |
| Moderate | 7.60 (4.29–10.9) | 5.25 (2.35–8.16) | 5.73 (3.23–8.26) | 4.02 (1.70–6.34) |
| High | 10.7 (7.15–14.2) | 5.48 (2.37–8.59) | 5.24 (2.57–7.91) | 5.43 (2.96–7.91) |
| Constant | 18.9 (12.2–25.7) | 7.76 (1.83–13.7) | 6.44 (3.28–9.60) | 5.17 (2.24–8.11) |
Change and 95% CI in Perceived Stress Scale (PSS) and Patient Health Questionnaire (PHQ)-15 scores adjusted for the following variables: years as an embryologist, full-time vs part-time/per-diem working status, and doctorate-level education. Bold denotes a statistically significant dose-dependent effect of cryostorage-related anxiety on PSS and PHQ-15 changes.